Archive for the ‘C-diff’ Category

DMSO Transforms The Treatment of Infectious Diseases

https://www.midwesterndoctor.com/p/dmso-transforms-the-treatment-of?

Clinical Considerations of Clostridia Bacterial Concerns:Part 2

https://biocidin.wistia.com/medias/vgvnolnqhj

Clinical Considerations of Clostridia Bacterial Concerns:  Part 2

Dr. Kurt Woeller opened our eyes to the breadth of symptoms that can manifest with Clostridium difficile and other pathogenic species in Part 1. So what’s the best way to confirm your suspicions that C. diff is involved?

In Part 2 Dr. Woeller identifies the methods he finds most effective for detecting C. diff in patients, including both conventionally accepted as well as alternative techniques:

  • Toxin detection via stool testing
  • Organic acids test
  • Stool analysis and culture

Learn from Dr. Woeller’s extensive experience as he discusses his expert recommendations on optimal laboratory testing methods.

You can watch the video in the link or read the article.

For more:  

Clinical Considerations of Clostridia Bacterial Concerns

https://biocidin.wistia.com/medias/wxusy0cfns Go here for presentation (Approx 22 Min)

Part 1: Clinical Considerations of Clostridia Bacterial Concerns – Pathogenicity Mechanisms

Biocidin Education Series

For more:  

Investigational C-diff Treatment Granted Fast Track Designation

http://outbreaknewstoday.com/investigational-clostridium-difficile-infection-treatment-granted-fast-track-designation-91368/

Investigational Clostridium difficile infection treatment granted Fast Track designation

January 16, 2019

Biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, Acurx Pharmaceuticals announced today that the U.S. Food and Drug Administration has granted Fast Track designation for ACX-362E, an investigational new treatment for Clostridium difficile Infection (CDI).  ACX-362E is a novel, oral antibiotic that recently entered Phase 1 development.

Clostridium difficile Image/CDC
Clostridium difficile
Image/CDC

ACX-362E is a novel, first-in-class, orally-administered antibacterial. It is the first of a novel class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections.

“The FDA’s decision to grant Fast Track Designation for ACX-362E corroborates our effort to develop a new, highly innovative treatment option for patients with CDI, an area of significant unmet need,” said Robert J. DeLuccia, Co-Founder & Managing Partner of Acurx. “If approved, we believe our new antibacterial, ACX-362E, will be an important therapeutic alternative for patients with CDI.  The Fast Track designation will allow Acurx to work more closely with the FDA to bring ACX-362E to physicians and patients as soon as possible.”

FDA Fast Track Designation is a process designed to facilitate the development and expedite the regulatory pathway of new drugs to treat serious or life-threatening conditions and that fill a high unmet medical need.

The CDC has reported that there are nearly 500,000 patients per year treated for CDI in the U.S. alone, with a recurrence rate approximated at 20% to 30%, with limited antibiotics available to treat patients with CDI.

OUTBREAK NEWS INTERVIEWS
Clostridium difficile awareness: A discussion with Steven LaRosa, MD

 

NTZ – Game Changer for Lyme Patients?

https://www.linkedin.com/pulse/nitazoxanide-known-killer-parasites-borrelia-cysts-booster-ozimek?trk=v feed&lipi=urn%3Ali%3Apage%3Ap_flagship3_feed%3BjOKiznIW%2BSs5upN50KaGRg%3D%3D

Is nitazoxanide (NTZ)- a real game changer for Lyme patients?
Written by:  Wojciech Piotr Ozimek, independent lecturer and researcher specialized in parasitic and vector-borne diseases.  Used with permission.

Nitazoxanide, a thiazolide compound, and its desacetyl derivative, tizoxanide, have antimicrobial properties against protozoa, cestodes, nematodes, trematodes, bacteria and viruses.

A retrospective review of charts of patients treated with nitazoxanide for infections caused by giardia lamblia, cryptosporidium parvum, blastocystis hominis, entamoeba histolytica, cyclospora, isospora and babesia caused infections demonstrated it’s high efficacy.

Unfortunately most of the studies showed that nitazoxanide is rather ineffective for the treatment of trichomoniasis.

Because the treatment of Helicobacter pylori infection may be jeopardized by metronidazole resistance, nitazoxanide and tizoxanide were tested in vitro and in vivo studies. Conclusions? It may be used as a single agent in the treatment of Helicobacter pylori and other Campylobacter sp. caused infections. It is also effective against Clostridium difficile caused infections.

There has been a study that claims there is some limited evidence for efficacy for SIBO (small intestinal bacterial overgrowth) in the context of an open label study, but no systematic review and all claims should be taken lightly.

Development of resistance to the two main classes of drugs used to treat intestinal nematode infections of humans has been reported. We need new and more effective drugs and ways to improve the efficacy of the old drugs. And again the promising alternative drug is nitazoxanide (NTZ). NTZ shown to have therapeutic activity against nematode (ascaris), cestode (taenia, hymenolepsis) and trematode (fasciola) infections. In addition NTZ combines synergistically with other classes of anthelmintic drugs, i.e. albendazole and pyrantel, making it a good candidate for further studies on its use in drug combination therapy of parasitic infections.

Lateef et al.. conducted a study in India that evaluated the effectiveness of nitazoxanide in the treatment of beef tapeworm (Taenia saginata) infection. They concluded that nitazoxanide is a well-tolerated drug for the treatment of niclosamide- and praziquantel-resistant beef tapeworm (Taenia saginata) infection.

It is also considered to be a “cyst busting” drug by some researchers, so can theoretically impact Borrelia, too. For these reasons, it is one of my favorite drugs, and in my opinion it should have a broader application for Lyme disease patients.

As if the above-mentioned benefits of nitazoxanide weren’t enough for some skeptics, the drug also impacts biofilm formation. This was shown by research published in Oxford’s Journal of Antimicrobial Chemotherapy, in a study entitled, “Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces.” Several other studies also demonstrate nitazoxanide’s inhibition of biofilm forming.

And lastly, nitazoxanide has even been shown to inhibit numerous viruses, including hepatitis B and C viruses, rotavirus and influenza A virus (in vitro).

To summarize, nitazoxanide can be used to kill protozoa, cestodes, nematodes, trematodes, bacteriae (incl. cysts & biofilm forms) and viruses.

It’s no wonder that Lyme patients, who are often afflicted with many of mentioned above infections, can feel so much better as a result of using nitazoxanide.

Nitazoxanide should be one of the most multi-talented and broadly applicable drugs available to Lyme sufferers, and I consider it to be one of the most important medicines presented in the last years.

Nitazoxanide is an effective, inexpensive, and generally safe and well tolerated medicine. In the clinical trials no serious adverse events were reported. Adverse events occur in less than 1% of the patients but physician monitoring is still advisable.

Nitazoxanide is sold under the brand names Nizonide, Nitaxide, Nitax, Zox, Netazox, Niazid, Toza, Daxon, Dexidex, Kidonax, Mitafar, Pacovanton, Paramix, Alinia, Adonid, NT-TOX, Nitamax,and Annita.